Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus
W. Riski Widya Mulyani,1 Made Indira Dianti Sanjiwani,1 Sandra,1 I Putu Yuda Prabawa,2 Anak Agung Wiradewi Lestari,2 Desak Made Wihandani,3 Ketut Suastika,4 Made Ratna Saraswati,4 Agha Bhargah,1,5 Ida Bagus Amertha Putra Manuaba6,7 1Faculty of Medicine, Universitas Udayana, Bali, Indonesia; 2Departm...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-02-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Subjects: | |
| Online Access: | https://www.dovepress.com/chaperone-based-therapeutic-target-innovation-heat-shock-protein-70-hs-peer-reviewed-article-DMSO |
| _version_ | 1797935402480304128 |
|---|---|
| author | Mulyani WRW Sanjiwani MID Sandra Prabawa IPY Lestari AAW Wihandani DM Suastika K Saraswati MR Bhargah A Manuaba IBAP |
| author_facet | Mulyani WRW Sanjiwani MID Sandra Prabawa IPY Lestari AAW Wihandani DM Suastika K Saraswati MR Bhargah A Manuaba IBAP |
| author_sort | Mulyani WRW |
| collection | DOAJ |
| description | W. Riski Widya Mulyani,1 Made Indira Dianti Sanjiwani,1 Sandra,1 I Putu Yuda Prabawa,2 Anak Agung Wiradewi Lestari,2 Desak Made Wihandani,3 Ketut Suastika,4 Made Ratna Saraswati,4 Agha Bhargah,1,5 Ida Bagus Amertha Putra Manuaba6,7 1Faculty of Medicine, Universitas Udayana, Bali, Indonesia; 2Department of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia; 3Department of Biochemistry, Faculty of Medicine, Universitas Udayana, Bali, Indonesia; 4Department of Internal Medicine, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia; 5Cardiology Department, Faculty of Medicine, Universitas Udayana-Sanglah General Hospital, Bali, Indonesia; 6International Ph.D Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 7Medical and Health Education Unit, Faculty of Medicine, Universitas Udayana, Bali, IndonesiaCorrespondence: Anak Agung Wiradewi LestariDepartment of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, IndonesiaEmail wiradewilestari@gmail.comAbstract: Type 2 diabetes mellitus (T2DM) is still a global health problem. Current T2DM treatments are limited to curing the symptoms and have not been able to restore insulin sensitivity in insulin-sensitive tissues that have become resistant. In the past decade, some studies have shown the significant role of a chaperone family, heat shock protein 70 (HSP70), in insulin resistance pathogenesis that leads to T2DM. HSP70 is a cytoprotective molecular chaperone that functions in protein folding and degradation. In general, studies have shown that decreased concentration of HSP70 is able to induce inflammation process through JNK activation, inhibit fatty acid oxidation by mitochondria through mitophagy decrease and mitochondrial biogenesis, as well as activate SREBP-1c, one of the lipogenic gene transcription factors in ER stress. The overall molecular pathways are potentially leading to insulin resistance and T2DM. Increased expression of HSP70 in brain tissues is able to improve insulin sensitivity and glycemic control specifically. HSP70 modulation-targeting strategies (including long-term physical exercise, hot tub therapy (HTT), and administration of alfalfa-derived HSP70 (aHSP70)) in subjects with insulin resistance are proven to have therapeutic and preventive potency that are promising in T2DM management.Keywords: type 2 diabetes mellitus, HSP70, insulin resistance |
| first_indexed | 2024-04-10T18:13:51Z |
| format | Article |
| id | doaj.art-8ce3edd7ec944ce28679c9254fdc6a7a |
| institution | Directory Open Access Journal |
| issn | 1178-7007 |
| language | English |
| last_indexed | 2024-04-10T18:13:51Z |
| publishDate | 2020-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj.art-8ce3edd7ec944ce28679c9254fdc6a7a2023-02-02T09:57:49ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072020-02-01Volume 1355956852124Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes MellitusMulyani WRWSanjiwani MIDSandraPrabawa IPYLestari AAWWihandani DMSuastika KSaraswati MRBhargah AManuaba IBAPW. Riski Widya Mulyani,1 Made Indira Dianti Sanjiwani,1 Sandra,1 I Putu Yuda Prabawa,2 Anak Agung Wiradewi Lestari,2 Desak Made Wihandani,3 Ketut Suastika,4 Made Ratna Saraswati,4 Agha Bhargah,1,5 Ida Bagus Amertha Putra Manuaba6,7 1Faculty of Medicine, Universitas Udayana, Bali, Indonesia; 2Department of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia; 3Department of Biochemistry, Faculty of Medicine, Universitas Udayana, Bali, Indonesia; 4Department of Internal Medicine, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, Indonesia; 5Cardiology Department, Faculty of Medicine, Universitas Udayana-Sanglah General Hospital, Bali, Indonesia; 6International Ph.D Program in Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 7Medical and Health Education Unit, Faculty of Medicine, Universitas Udayana, Bali, IndonesiaCorrespondence: Anak Agung Wiradewi LestariDepartment of Clinical Pathology, Faculty of Medicine, Universitas Udayana, Sanglah General Hospital, Bali, IndonesiaEmail wiradewilestari@gmail.comAbstract: Type 2 diabetes mellitus (T2DM) is still a global health problem. Current T2DM treatments are limited to curing the symptoms and have not been able to restore insulin sensitivity in insulin-sensitive tissues that have become resistant. In the past decade, some studies have shown the significant role of a chaperone family, heat shock protein 70 (HSP70), in insulin resistance pathogenesis that leads to T2DM. HSP70 is a cytoprotective molecular chaperone that functions in protein folding and degradation. In general, studies have shown that decreased concentration of HSP70 is able to induce inflammation process through JNK activation, inhibit fatty acid oxidation by mitochondria through mitophagy decrease and mitochondrial biogenesis, as well as activate SREBP-1c, one of the lipogenic gene transcription factors in ER stress. The overall molecular pathways are potentially leading to insulin resistance and T2DM. Increased expression of HSP70 in brain tissues is able to improve insulin sensitivity and glycemic control specifically. HSP70 modulation-targeting strategies (including long-term physical exercise, hot tub therapy (HTT), and administration of alfalfa-derived HSP70 (aHSP70)) in subjects with insulin resistance are proven to have therapeutic and preventive potency that are promising in T2DM management.Keywords: type 2 diabetes mellitus, HSP70, insulin resistancehttps://www.dovepress.com/chaperone-based-therapeutic-target-innovation-heat-shock-protein-70-hs-peer-reviewed-article-DMSOtype 2 diabetes mellitushsp70insulin resistance. |
| spellingShingle | Mulyani WRW Sanjiwani MID Sandra Prabawa IPY Lestari AAW Wihandani DM Suastika K Saraswati MR Bhargah A Manuaba IBAP Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus Diabetes, Metabolic Syndrome and Obesity type 2 diabetes mellitus hsp70 insulin resistance. |
| title | Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus |
| title_full | Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus |
| title_fullStr | Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus |
| title_full_unstemmed | Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus |
| title_short | Chaperone-Based Therapeutic Target Innovation: Heat Shock Protein 70 (HSP70) for Type 2 Diabetes Mellitus |
| title_sort | chaperone based therapeutic target innovation heat shock protein 70 hsp70 for type 2 diabetes mellitus |
| topic | type 2 diabetes mellitus hsp70 insulin resistance. |
| url | https://www.dovepress.com/chaperone-based-therapeutic-target-innovation-heat-shock-protein-70-hs-peer-reviewed-article-DMSO |
| work_keys_str_mv | AT mulyaniwrw chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT sanjiwanimid chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT sandra chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT prabawaipy chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT lestariaaw chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT wihandanidm chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT suastikak chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT saraswatimr chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT bhargaha chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus AT manuabaibap chaperonebasedtherapeutictargetinnovationheatshockprotein70hsp70fortype2diabetesmellitus |